Skip to content

Author

R. McIntyre

9 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Nov 2026

Efficacy of Lumateperone 42 mg in Major Depressive Disorder: Subgroup Analysis of a Phase 3 Randomized, Placebo-Controlled Trial.

Objective: Lumateperone is an FDA-approved atypical antipsychotic to treat schizophrenia, bipolar I or II depression, and major depressive disorder (MDD). Post hoc analyses of a randomized, phase 3, double-blind, placebo-controlled trial (Study 501) evaluated the efficacy of lumateperone 42 mg adjunctive to antidepress...

S. Durgam, W. Earley, R. Migliore et al. · 0 citations
Review Open access Oct 2026

Effect of electroconvulsive therapy on anhedonia in adults with major depressive disorder: A systematic review and meta-analysis.

ECT was associated with a statistically significant improvement in anhedonia among adults with MDD, and future ECT studies should assess anhedonia as an outcome, while using a validated anhedonia measure.

Ryan Radmard, Kristoffer J. Panganiban, Angela T. H. Kwan et al. · 0 citations
Review Open access Oct 2026

Psilocybin for anhedonia in unipolar and bipolar depression: A systematic review of clinical and preclinical evidence.

BACKGROUND Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in major depressive disorder (MDD), however, its effects on anhedonia specifically have yet to be...

Erica S. Kaczmarek, Sabrina Wong, Noah Chisamore et al. · 0 citations
Review Open access Oct 2026

Exploring the durability of esketamine and ketamine's antidepressant effects in the maintenance phase of treatment: A systematic review.

Ketamine has shown rapid antidepressant effects in treatment-resistant mood disorders; however, the durability of these benefits during maintenance treatment remains unclear. This systematic review evaluated outcomes associated with repeated ketamine and esketamine administration during the maintenance phase of treatme...

Shreya Vasudeva, Diana K. Orsini, Gabrielle F. M. Lovell et al. · 0 citations
Review Open access Oct 2026

Efficacy and safety of GLP-1 receptor agonists in patients with schizophrenia spectrum disorders treated with antipsychotics: a systematic review and meta-analysis.

Weight gain and impaired glucose metabolism are common complications of antipsychotic treatment in schizophrenia spectrum disorders (SSD). While beneficial in other populations, the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in SSD remain unclear. We conducted a systematic review and m...

A. Gędek, Szymon Modrzejewski, Krzysztof Polański et al. · 0 citations
Open access Oct 2026

An fNIRS investigation of cortical responses to expressed emotion in bipolar disorder.

Findings indicate region- and context-specific differences in cortical hemodynamic responses and functional coupling in individuals with BD during EE processing may serve as candidate features for further investigation in larger and independent studies.

Cui-Yan Wang, Yue-Qian Zhang, Wei Zhang et al. · 0 citations
Review Open access Sep 2026

Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review.

BACKGROUND Many proteins integral to psychotropic agents' pharmacokinetics (PK) and pharmacodynamics (PD) exhibit circadian variation in expression and function. Chronopharmacology examines the effect of circadian systems on the pharmacology of drugs. Herein, we review the impact of circadian rhythm on drug-metabolizin...

Victoria Yue Tan, Sabrina Wong, Gia-Han Le et al. · 0 citations
Review Aug 2026

A Systematic Review of Long-term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-resistant Depression.

Current evidence supports the safety of ketamine and esketamine for TRD, with no cumulative organ toxicity or iatrogenic addiction during maintenance treatment, but findings are limited by heterogeneity in safety monitoring across studies.

Tychique T. Wasolua, Morgan Hardy, Tanner J. Bommersbach et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.